Last Updated : May 5, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Truxima | Rituximab | Cancelled | ||||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending |
Last Updated : May 5, 2024